Literature DB >> 22196333

Role for mTOR signaling and neuronal activity in morphine-induced adaptations in ventral tegmental area dopamine neurons.

Michelle S Mazei-Robison1, Ja Wook Koo, Allyson K Friedman, Carien S Lansink, Alfred J Robison, Monika Vinish, Vaishnav Krishnan, Seyun Kim, Michael A Siuta, Aurelio Galli, Kevin D Niswender, Raghu Appasani, Monika C Horvath, Rachel L Neve, Paul F Worley, Solomon H Snyder, Yasmin L Hurd, Joseph F Cheer, Ming-Hu Han, Scott J Russo, Eric J Nestler.   

Abstract

While the abuse of opiate drugs continues to rise, the neuroadaptations that occur with long-term drug exposure remain poorly understood. We describe here a series of chronic morphine-induced adaptations in ventral tegmental area (VTA) dopamine neurons, which are mediated via downregulation of AKT-mTORC2 (mammalian target of rapamycin complex-2). Chronic opiates decrease the size of VTA dopamine neurons in rodents, an effect seen in humans as well, and concomitantly increase the excitability of the cells but decrease dopamine output to target regions. Chronic morphine decreases mTORC2 activity, and overexpression of Rictor, a component of mTORC2, prevents morphine-induced changes in cell morphology and activity. Further, local knockout of Rictor in VTA decreases DA soma size and reduces rewarding responses to morphine, consistent with the hypothesis that these adaptations represent a mechanism of reward tolerance. Together, these findings demonstrate a novel role for AKT-mTORC2 signaling in mediating neuroadaptations to opiate drugs of abuse.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22196333      PMCID: PMC3246191          DOI: 10.1016/j.neuron.2011.10.012

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  54 in total

Review 1.  Neural mechanisms of addiction: the role of reward-related learning and memory.

Authors:  Steven E Hyman; Robert C Malenka; Eric J Nestler
Journal:  Annu Rev Neurosci       Date:  2006       Impact factor: 12.449

2.  No effect of morphine on ventral tegmental dopamine neurons during withdrawal.

Authors:  François Georges; Catherine Le Moine; Gary Aston-Jones
Journal:  J Neurosci       Date:  2006-05-24       Impact factor: 6.167

3.  Role for Akt3/protein kinase Bgamma in attainment of normal brain size.

Authors:  Rachael M Easton; Han Cho; Kristin Roovers; Diana W Shineman; Moshe Mizrahi; Mark S Forman; Virginia M-Y Lee; Matthias Szabolcs; Ron de Jong; Tilman Oltersdorf; Thomas Ludwig; Argiris Efstratiadis; Morris J Birnbaum
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

4.  Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action.

Authors:  Nadia M Tsankova; Olivier Berton; William Renthal; Arvind Kumar; Rachel L Neve; Eric J Nestler
Journal:  Nat Neurosci       Date:  2006-02-26       Impact factor: 24.884

5.  Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene.

Authors:  W S Chen; P Z Xu; K Gottlob; M L Chen; K Sokol; T Shiyanova; I Roninson; W Weng; R Suzuki; K Tobe; T Kadowaki; N Hay
Journal:  Genes Dev       Date:  2001-09-01       Impact factor: 11.361

6.  Regulation of gene expression by chronic morphine and morphine withdrawal in the locus ceruleus and ventral tegmental area.

Authors:  Colleen A McClung; Eric J Nestler; Venetia Zachariou
Journal:  J Neurosci       Date:  2005-06-22       Impact factor: 6.167

7.  Morphine withdrawal-induced abnormalities in the VTA: confocal laser scanning microscopy.

Authors:  Saturnino Spiga; Giuliana P Serra; M Cristina Puddu; Marzia Foddai; Marco Diana
Journal:  Eur J Neurosci       Date:  2003-02       Impact factor: 3.386

Review 8.  Growing roles for the mTOR pathway.

Authors:  Dos D Sarbassov; Siraj M Ali; David M Sabatini
Journal:  Curr Opin Cell Biol       Date:  2005-10-13       Impact factor: 8.382

9.  Removal of FKBP12 enhances mTOR-Raptor interactions, LTP, memory, and perseverative/repetitive behavior.

Authors:  Charles A Hoeffer; Wei Tang; Helen Wong; Arturo Santillan; Richard J Patterson; Luis A Martinez; Maria V Tejada-Simon; Richard Paylor; Susan L Hamilton; Eric Klann
Journal:  Neuron       Date:  2008-12-10       Impact factor: 17.173

10.  Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress.

Authors:  Olivier Berton; Colleen A McClung; Ralph J Dileone; Vaishnav Krishnan; William Renthal; Scott J Russo; Danielle Graham; Nadia M Tsankova; Carlos A Bolanos; Maribel Rios; Lisa M Monteggia; David W Self; Eric J Nestler
Journal:  Science       Date:  2006-02-10       Impact factor: 47.728

View more
  60 in total

1.  Essential role of D1R in the regulation of mTOR complex1 signaling induced by cocaine.

Authors:  Laurie P Sutton; Marc G Caron
Journal:  Neuropharmacology       Date:  2015-08-24       Impact factor: 5.250

2.  Septal Glucagon-Like Peptide 1 Receptor Expression Determines Suppression of Cocaine-Induced Behavior.

Authors:  Anne E Harasta; John M Power; Georg von Jonquieres; Tim Karl; Daniel J Drucker; Gary D Housley; Miriam Schneider; Matthias Klugmann
Journal:  Neuropsychopharmacology       Date:  2015-02-11       Impact factor: 7.853

3.  ΔFosB induction in striatal medium spiny neuron subtypes in response to chronic pharmacological, emotional, and optogenetic stimuli.

Authors:  Mary Kay Lobo; Samir Zaman; Diane M Damez-Werno; Ja Wook Koo; Rosemary C Bagot; Jennifer A DiNieri; Alexandria Nugent; Eric Finkel; Dipesh Chaudhury; Ramesh Chandra; Efrain Riberio; Jacqui Rabkin; Ezekiell Mouzon; Roger Cachope; Joseph F Cheer; Ming-Hu Han; David M Dietz; David W Self; Yasmin L Hurd; Vincent Vialou; Eric J Nestler
Journal:  J Neurosci       Date:  2013-11-20       Impact factor: 6.167

4.  mTORC2/rictor signaling disrupts dopamine-dependent behaviors via defects in striatal dopamine neurotransmission.

Authors:  Olga I Dadalko; Michael Siuta; Amanda Poe; Kevin Erreger; Heinrich J G Matthies; Kevin Niswender; Aurelio Galli
Journal:  J Neurosci       Date:  2015-06-10       Impact factor: 6.167

5.  Mechanisms of psychostimulant-induced structural plasticity.

Authors:  Sam A Golden; Scott J Russo
Journal:  Cold Spring Harb Perspect Med       Date:  2012-10-01       Impact factor: 6.915

6.  mTORC2 in the dorsomedial striatum of mice contributes to alcohol-dependent F-Actin polymerization, structural modifications, and consumption.

Authors:  Sophie Laguesse; Nadege Morisot; Khanhky Phamluong; Samuel A Sakhai; Dorit Ron
Journal:  Neuropsychopharmacology       Date:  2018-02-07       Impact factor: 7.853

7.  Morphine and cocaine increase serum- and glucocorticoid-inducible kinase 1 activity in the ventral tegmental area.

Authors:  Elizabeth A Heller; Sophia Kaska; Barbara Fallon; Deveroux Ferguson; Pamela J Kennedy; Rachael L Neve; Eric J Nestler; Michelle S Mazei-Robison
Journal:  J Neurochem       Date:  2014-08-26       Impact factor: 5.372

8.  Enduring deficits in brain reward function after chronic social defeat in rats: susceptibility, resilience, and antidepressant response.

Authors:  Andre Der-Avakian; Michelle S Mazei-Robison; James P Kesby; Eric J Nestler; Athina Markou
Journal:  Biol Psychiatry       Date:  2014-01-31       Impact factor: 13.382

9.  Acute Morphine, Chronic Morphine, and Morphine Withdrawal Differently Affect Pleiotrophin, Midkine, and Receptor Protein Tyrosine Phosphatase β/ζ Regulation in the Ventral Tegmental Area.

Authors:  Daniel García-Pérez; M Luisa Laorden; M Victoria Milanés
Journal:  Mol Neurobiol       Date:  2016-01-07       Impact factor: 5.590

10.  BDNF is a negative modulator of morphine action.

Authors:  Ja Wook Koo; Michelle S Mazei-Robison; Dipesh Chaudhury; Barbara Juarez; Quincey LaPlant; Deveroux Ferguson; Jian Feng; Haosheng Sun; Kimberly N Scobie; Diane Damez-Werno; Marshall Crumiller; Yoshinori N Ohnishi; Yoko H Ohnishi; Ezekiell Mouzon; David M Dietz; Mary Kay Lobo; Rachael L Neve; Scott J Russo; Ming-Hu Han; Eric J Nestler
Journal:  Science       Date:  2012-10-05       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.